Towards a unified protocol for handling of CSF before β-amyloid measurements.

Abstract:

BACKGROUND:Widespread implementation of Alzheimer's disease biomarkers in routine clinical practice requires the establishment of standard operating procedures for pre-analytical handling of cerebrospinal fluid (CSF). METHODS:Here, CSF collection and storage protocols were optimized for measurements of β-amyloid (Aβ). We investigated the effects of (1) storage temperature, (2) storage time, (3) centrifugation, (4) sample mixing, (5) blood contamination, and (6) collection gradient on CSF levels of Aβ. For each study participant, we used fresh CSF directly collected into a protein low binding (LoB) tube that was analyzed within hours after lumbar puncture (LP) as standard of truth. Aβ42 and Aβ40 were measured in de-identified CSF samples using EUROIMMUN and Mesoscale discovery assays. RESULTS:CSF Aβ42 and Aβ40 were stable for at least 72 h at room temperature (RT), 1 week at 4 °C, and 2 weeks at - 20 °C and - 80 °C. Centrifugation of non-blood-contaminated CSF or mixing of samples before the analysis did not affect Aβ levels. Addition of 0.1-10% blood to CSF that was stored at RT without centrifugation led to a dose- and time-dependent decrease in Aβ42 and Aβ40, while Aβ42/Aβ40 did not change. The effects of blood contamination were mitigated by centrifugation and/or storage at 4 °C or - 20 °C. Aβ levels did not differ between the first to fourth 5-ml portions of CSF. CONCLUSIONS:CSF can be stored for up to 72 h at RT, 1 week at 4 °C, or at least 2 weeks at either - 20 °C or - 80 °C before Aβ measurements. Centrifugation of fresh non-blood-contaminated CSF after LP, or mixing before analysis, is not required. In case of visible blood contamination, centrifugation and storage at 4 °C or - 20 °C is recommended. After discarding the first 2 ml, any portion of up to 20 ml of CSF is suitable for Aβ analysis. These findings will be important for the development of a clinical routine protocol for pre-analytical handling of CSF.

journal_name

Alzheimers Res Ther

authors

Janelidze S,Stomrud E,Brix B,Hansson O

doi

10.1186/s13195-019-0517-9

subject

Has Abstract

pub_date

2019-07-19 00:00:00

pages

63

issue

1

issn

1758-9193

pii

10.1186/s13195-019-0517-9

journal_volume

11

pub_type

杂志文章
  • Systematic reviews on behavioural and psychological symptoms in the older or demented population.

    abstract:INTRODUCTION:Behavioural and psychological symptoms of dementia (BPS) include depressive symptoms, anxiety, apathy, sleep problems, irritability, psychosis, wandering, elation and agitation, and are common in the non-demented and demented population. METHODS:We have undertaken a systematic review of reviews to give a ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt131

    authors: van der Linde RM,Stephan BC,Savva GM,Dening T,Brayne C

    更新日期:2012-07-11 00:00:00

  • Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.

    abstract::Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson's disease dementia, affects over a million people in the USA and has a substantial impact on patients, caregivers, and society. Symptomatic treatments for LBD, which can include cognitive, neuropsychiatric, autonomic, sleep, and motor features...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-020-00703-5

    authors: Goldman JG,Forsberg LK,Boeve BF,Armstrong MJ,Irwin DJ,Ferman TJ,Galasko D,Galvin JE,Kaufer D,Leverenz J,Lippa CF,Marder K,Abler V,Biglan K,Irizarry M,Keller B,Munsie L,Nakagawa M,Taylor A,Graham T

    更新日期:2020-10-29 00:00:00

  • Dystrophic neurites express C9orf72 in Alzheimer's disease brains.

    abstract:INTRODUCTION:Chromosome 9 open reading frame 72 (C9orf72) is an evolutionarily conserved protein with unknown function, expressed at high levels in the brain. An expanded hexanucleotide GGGGCC repeat located in the first intron of the C9orf72 gene represents the most common genetic cause of familial frontotemporal deme...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt136

    authors: Satoh J,Tabunoki H,Ishida T,Saito Y,Arima K

    更新日期:2012-08-16 00:00:00

  • The effects of different familial Alzheimer's disease mutations on APP processing in vivo.

    abstract:BACKGROUND:Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer's disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a model for the sporadic form of AD. In FAD the diagnosis of AD is reliable and presymptomatic individu...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0234-1

    authors: Thordardottir S,Kinhult Ståhlbom A,Almkvist O,Thonberg H,Eriksdotter M,Zetterberg H,Blennow K,Graff C

    更新日期:2017-02-16 00:00:00

  • Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.

    abstract:INTRODUCTION:Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosi...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0143-0

    authors: Coutinho AM,Porto FH,Duran FL,Prando S,Ono CR,Feitosa EA,Spíndola L,de Oliveira MO,do Vale PH,Gomes HR,Nitrini R,Brucki SM,Buchpiguel CA

    更新日期:2015-09-15 00:00:00

  • The Third French Alzheimer Plan: analysis of the influence of a national public health initiative on scientific research productivity and impact.

    abstract:INTRODUCTION:The Third National Alzheimer Plan (2008-2012) was a major public health initiative in France that included €200 million of funding for research in Alzheimer disease and related disorders (AD). The aim of this study was to document trends in French academic output in AD following the implementation of the p...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0144-z

    authors: Haeffner-Cavaillon N,Devos P,Ledoux S,Ménard J

    更新日期:2015-09-26 00:00:00

  • An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.

    abstract:INTRODUCTION:Amyloid-β (Aβ) has been investigated as a diagnostic biomarker and therapeutic drug target. Recent studies found that cerebrospinal fluid (CSF) Aβ fluctuates over time, including as a diurnal pattern, and increases in absolute concentration with serial collection. It is currently unknown what effect differ...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章

    doi:10.1186/s13195-015-0136-z

    authors: Lucey BP,Gonzales C,Das U,Li J,Siemers ER,Slemmon JR,Bateman RJ,Huang Y,Fox GB,Claassen JA,Slats D,Verbeek MM,Tong G,Soares H,Savage MJ,Kennedy M,Forman M,Sjögren M,Margolin R,Chen X,Farlow MR,Dean RA,Waring J

    更新日期:2015-07-29 00:00:00

  • Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease.

    abstract:INTRODUCTION:There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testostero...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0107-4

    authors: Hall JR,Wiechmann AR,Cunningham RL,Johnson LA,Edwards M,Barber RC,Singh M,Winter S,O'Bryant SE,Texas Alzheimer’s Research and Care Consortium.

    更新日期:2015-05-01 00:00:00

  • Prediction models for dementia and neuropathology in the oldest old: the Vantaa 85+ cohort study.

    abstract:BACKGROUND:We developed multifactorial models for predicting incident dementia and brain pathology in the oldest old using the Vantaa 85+ cohort. METHODS:We included participants without dementia at baseline and at least 2 years of follow-up (N = 245) for dementia prediction or with autopsy data (N = 163) for patholog...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0450-3

    authors: Hall A,Pekkala T,Polvikoski T,van Gils M,Kivipelto M,Lötjönen J,Mattila J,Kero M,Myllykangas L,Mäkelä M,Oinas M,Paetau A,Soininen H,Tanskanen M,Solomon A

    更新日期:2019-01-22 00:00:00

  • Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.

    abstract:INTRODUCTION:Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well as effects on reducing beta-amyloid aggregation. It reduces pathology in transgenic models of Alzheimer's disease (AD) and is a promising candidat...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt146

    authors: Ringman JM,Frautschy SA,Teng E,Begum AN,Bardens J,Beigi M,Gylys KH,Badmaev V,Heath DD,Apostolova LG,Porter V,Vanek Z,Marshall GA,Hellemann G,Sugar C,Masterman DL,Montine TJ,Cummings JL,Cole GM

    更新日期:2012-10-29 00:00:00

  • Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial.

    abstract:INTRODUCTION:The long-term efficacy and safety of donepezil 10 mg in patients with dementia with Lewy bodies (DLB) were investigated in a 52-week Phase 3 trial. METHODS:This 52-week study consisted of 16-week randomized placebo-controlled (RCT) and 36-week open-label extension phases. Of 142 DLB patients enrolled in t...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-014-0081-2

    authors: Mori E,Ikeda M,Nagai R,Matsuo K,Nakagawa M,Kosaka K

    更新日期:2015-02-03 00:00:00

  • Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimer's disease-associated markers in 3xTg-AD mice.

    abstract:BACKGROUND:Circulating autoantibodies and sex-dependent discrepancy in prevalence are unexplained phenomena of Alzheimer's disease (AD). Using the 3xTg-AD mouse model, we reported that adult males show early manifestations of systemic autoimmunity, increased emotional reactivity, enhanced expression of the histone vari...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00745-9

    authors: Kapadia M,Mian MF,Ma D,Hutton CP,Azam A,Narkaj K,Cao C,Brown B,Michalski B,Morgan D,Forsythe P,Zovkic IB,Fahnestock M,Sakic B

    更新日期:2021-01-20 00:00:00

  • Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.

    abstract:BACKGROUND:Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by neuropathologic changes involving beta-amyloid (Aβ), tau, neuronal loss, and other associated biological events. While levels of cerebrospinal fluid (CSF) Aβ and tau peptides have enhanced the antemortem detection of AD-specifi...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13195-018-0426-3

    authors: Gangishetti U,Christina Howell J,Perrin RJ,Louneva N,Watts KD,Kollhoff A,Grossman M,Wolk DA,Shaw LM,Morris JC,Trojanowski JQ,Fagan AM,Arnold SE,Hu WT

    更新日期:2018-09-25 00:00:00

  • The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study.

    abstract:BACKGROUND:Approximately 25% of the general population carries at least one ε4 allele of the Apolipoprotein E (APOE ε4), the strongest genetic risk factor for late onset Alzheimer's disease. Beyond its association with late-onset dementia, the association between APOE ε4 and change in cognition over the adult life cour...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00740-0

    authors: Gharbi-Meliani A,Dugravot A,Sabia S,Regy M,Fayosse A,Schnitzler A,Kivimäki M,Singh-Manoux A,Dumurgier J

    更新日期:2021-01-04 00:00:00

  • The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.

    abstract:BACKGROUND:Synapse damage and loss are fundamental to the pathophysiology of Alzheimer's disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD therapeutics that can demonstrate reduction of synapse damage or loss. ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-020-00588-4

    authors: Colom-Cadena M,Spires-Jones T,Zetterberg H,Blennow K,Caggiano A,DeKosky ST,Fillit H,Harrison JE,Schneider LS,Scheltens P,de Haan W,Grundman M,van Dyck CH,Izzo NJ,Catalano SM,Synaptic Health Endpoints Working Group.

    更新日期:2020-03-02 00:00:00

  • Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer's disease: a nationwide matched cohort study.

    abstract:BACKGROUND:Antidepressant use has been associated with an increased risk of falling, but no studies have been conducted on whether antidepressant use is associated with an increased risk of head injuries which often result from falling among older persons. The objective of this study was to investigate the risk of head...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0285-3

    authors: Taipale H,Koponen M,Tanskanen A,Lavikainen P,Sund R,Tiihonen J,Hartikainen S,Tolppanen AM

    更新日期:2017-08-01 00:00:00

  • Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.

    abstract:BACKGROUND:Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer's disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomar...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0545-5

    authors: Ashton NJ,Suárez-Calvet M,Heslegrave A,Hye A,Razquin C,Pastor P,Sanchez-Valle R,Molinuevo JL,Visser PJ,Blennow K,Hodges AK,Zetterberg H

    更新日期:2019-11-28 00:00:00

  • Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.

    abstract:BACKGROUND:Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0477-0

    authors: Startin CM,Ashton NJ,Hamburg S,Hithersay R,Wiseman FK,Mok KY,Hardy J,Lleó A,Lovestone S,Parnetti L,Zetterberg H,Hye A,LonDownS Consortium.,Strydom A

    更新日期:2019-03-21 00:00:00

  • Compression or expansion of dementia in Germany? An observational study of short-term trends in incidence and death rates of dementia between 2006/07 and 2009/10 based on German health insurance data.

    abstract:INTRODUCTION:There have been recent reports about a decline in dementia incidence, but only little is known about trends in the mortality of patients with dementia. Only the simultaneous analysis of both trends can inform whether the reported decline in dementia has led to a compression of dementia into higher ages. M...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0146-x

    authors: Doblhammer G,Fink A,Zylla S,Willekens F

    更新日期:2015-11-05 00:00:00

  • Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery.

    abstract::The Alzheimer's Drug Discovery Foundation's 13th International Conference on Alzheimer's Drug Discovery was held on 10-11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alzheimer's Drug Discovery Foundation-funded programs, ranging from novel biomarkers to accelerate clinical devel...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt159

    authors: Lane RF,Dacks PA,Shineman DW,Fillit HM

    更新日期:2013-02-04 00:00:00

  • Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.

    abstract:BACKGROUND:Disclosure of amyloid positron emission tomography (PET) results to individuals without dementia has become standard practice in secondary prevention trials and also increasingly occurs in clinical practice. However, this is controversial given the current lack of understanding of the predictive value of a P...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0398-3

    authors: de Wilde A,van Buchem MM,Otten RHJ,Bouwman F,Stephens A,Barkhof F,Scheltens P,van der Flier WM

    更新日期:2018-07-28 00:00:00

  • Amyloid β-protein oligomers and Alzheimer's disease.

    abstract::The oligomer cascade hypothesis, which states that oligomers are the initiating pathologic agents in Alzheimer's disease, has all but supplanted the amyloid cascade hypothesis, which suggested that fibers were the key etiologic agents in Alzheimer's disease. We review here the results of in vivo, in vitro and in silic...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt226

    authors: Hayden EY,Teplow DB

    更新日期:2013-11-29 00:00:00

  • Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.

    abstract:BACKGROUND:Determination of β-amyloid (Aβ) positivity and likelihood of underlying Alzheimer's disease (AD) relies on dichotomous biomarker cut-off values. Individuals with mild cognitive impairment (MCI) and Aβ within the normal range may still have a substantial risk of developing dementia, primarily of Alzheimer typ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0557-1

    authors: Rosenberg A,Solomon A,Jelic V,Hagman G,Bogdanovic N,Kivipelto M

    更新日期:2019-12-05 00:00:00

  • Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals.

    abstract:BACKGROUND:Amyloid pathology, which is one of the characteristics of Alzheimer's disease (AD), results from altered metabolism of the beta-amyloid (Aβ) peptide in terms of synthesis, clearance, or aggregation. A decrease in cerebrospinal fluid (CSF) level Aβ1-42 is evident in AD, and the CSF ratio Aβ42/Aβ40 has recentl...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00696-1

    authors: Lehmann S,Dumurgier J,Ayrignac X,Marelli C,Alcolea D,Ormaechea JF,Thouvenot E,Delaby C,Hirtz C,Vialaret J,Ginestet N,Bouaziz-Amar E,Laplanche JL,Labauge P,Paquet C,Lleo A,Gabelle A,Alzheimer’s Disease Neuroimaging Initi

    更新日期:2020-10-02 00:00:00

  • Potential sources of interference on Abeta immunoassays in biological samples.

    abstract::Therapeutic products that depend on the use of an in vitro diagnostic biomarker test to confirm their effectiveness are increasingly being developed. Use of biomarkers is particularly meaningful in the context of selecting the patient population where the therapeutic treatment is believed to be efficacious (patient en...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt142

    authors: Vanderstichele H,Stoops E,Vanmechelen E,Jeromin A

    更新日期:2012-10-17 00:00:00

  • Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander?

    abstract::The strongest known risk factors for late-onset Alzheimer disease (LOAD) remain a positive family history and the APOE epsilon4 allele. van Exel and colleagues used these known risk factors to identify high- and low-risk samples of middle-aged persons in whom they compared levels of inflammatory and vascular risk fact...

    journal_title:Alzheimer's research & therapy

    pub_type: 社论

    doi:10.1186/alzrt29

    authors: Tan ZS,Seshadri S

    更新日期:2010-04-12 00:00:00

  • The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

    abstract:INTRODUCTION:Depression and psychosis are two of the most severe neuropsychiatric symptoms (NPS) in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Both NPS have negative effects on cognitive performance and life expectancy. The current study aimed to investigate and compare monoaminergic etiologies betwe...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-014-0090-1

    authors: Vermeiren Y,Van Dam D,Aerts T,Engelborghs S,Martin JJ,De Deyn PP

    更新日期:2015-02-11 00:00:00

  • Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.

    abstract:BACKGROUND:Amyloid-β 1-42 (Aβ1-42) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer's disease (AD). Reduced levels of Aβ1-42 are indicative of AD, but significant variation in the absolute concentrations of this analyte has been described for both healthy and diseased populations. Preanal...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0445-0

    authors: Schauer SP,Mylott WR Jr,Yuan M,Jenkins RG,Rodney Mathews W,Honigberg LA,Wildsmith KR

    更新日期:2018-11-28 00:00:00

  • Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.

    abstract:BACKGROUND:The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-making for multicentre research studies and clinical trials. In this study, we aimed at deriving reference Ce...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0478-z

    authors: Salvadó G,Molinuevo JL,Brugulat-Serrat A,Falcon C,Grau-Rivera O,Suárez-Calvet M,Pavia J,Niñerola-Baizán A,Perissinotti A,Lomeña F,Minguillon C,Fauria K,Zetterberg H,Blennow K,Gispert JD,Alzheimer’s Disease Neuroimaging Init

    更新日期:2019-03-21 00:00:00

  • Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody.

    abstract:BACKGROUND:Amyloid-β (Aβ) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer's disease (AD). Despite recent progress targeting aggregated forms of Aβ, low antibody brain penetrance remains a challenge. In the present study, we used transferrin receptor (TfR)-mediated transcytosis to f...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0377-8

    authors: Syvänen S,Hultqvist G,Gustavsson T,Gumucio A,Laudon H,Söderberg L,Ingelsson M,Lannfelt L,Sehlin D

    更新日期:2018-05-24 00:00:00